Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22990727 | 1.00 | L3MBTL1 (0.48) | L3MBTL1NAMPTBRD4MEN1POLB | |
| SCHEMBL22981083 | 0.85 | L3MBTL1 (0.55) | L3MBTL1BRD4HDAC3HDAC4HDAC1 | |
| SCHEMBL31497538 | 0.84 | NOD1 (0.40) | L3MBTL1NAMPTBRD4MEN1POLB | |
| SCHEMBL30007018 | 0.82 | L3MBTL1 (0.43) | L3MBTL1NAMPTMEN1POLBKMT2A | |
| SCHEMBL1536091 | 0.82 | L3MBTL1 (0.43) | L3MBTL1NAMPTMEN1POLBKMT2A | |
| SCHEMBL22990705 | 0.79 | L3MBTL1 (0.59) | L3MBTL1BRD4POLBHDAC3HDAC4 | |
| SCHEMBL22990912 | 0.78 | HTR6 (0.51) | MEN1KMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22980753 | 0.77 | L3MBTL1 (0.47) | L3MBTL1BRD4MEN1KMT2AHDAC3 | |
| SCHEMBL23970981 | 0.76 | CYP2C19 (0.45) | L3MBTL1MEN1POLBKMT2AHDAC3 | |
| SCHEMBL1536041 | 0.74 | L3MBTL1 (0.42) | L3MBTL1NAMPTMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4010080-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | L3MBTL1 4404/4885NAMPT 281/4885BRD4 883/4885 |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | L3MBTL1 4404/4885NAMPT 281/4885BRD4 883/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | L3MBTL1 3995/4885NAMPT 124/4885BRD4 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.